Esatec 20/Esatec 40 Side Effects

Summary of the safety profile: The most commonly reported adverse reactions during treatment with Olmesartan are headache (7.7%), influenza-like symptoms (4.0%) and dizziness (3.7%).
In placebo-controlled monotherapy studies, the only adverse drug reaction unequivocally related to treatment was dizziness (2.5% incidence on Olmesartan medoxomil and 0.9% on placebo).
The incidence was also somewhat higher on Olmesartan medoxomil compared with placebo for hypertriglyceridemia phosphokinase (2.0% versus 1.1%) and for raised creatine phosphokinase (1.3% versus 0.7%).
Tabulated list of adverse reactions: Adverse reactions from Olmesartan in clinical trials, post-authorization safety studies and spontaneous reporting are summarized in the table as follows.
The following terminologies have been used in order to classify the occurrence of adverse reactions: very common (≥1/10); common (≥1/100 to 1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000). (See table.)

Click on icon to see table/diagram/image

Single cases of rhabdomyolysis have been reported in temporal association with the intake of angiotensin II receptor blockers.
Additional information on special populations: Elderly (age 65 years or over): In elderly people the frequency of hypotension is slightly increased from rare to uncommon.